Sarah Skerrat

Dr. Sarah Skerratt is an organic chemist by training, conducting her PhD with Professor J C Anderson at the University of Nottingham before undertaking postdoctoral studies with Professor P A Wender at Stanford University as a visiting Fulbright Scholar. Sarah began her industrial career as a medicinal chemist at Pfizer, UK and has subsequently taken on roles at Convergence, Vertex and MSD.  Sarah is currently SVP, Head of Drug Discovery at CHARM Therapeutics, harnessing the power of deep learning on 3D molecular configurations to deliver medicines of transformational efficacy to patients. In her 18 years of drug discovery, she has contributed to the delivery of multiple clinical stage compounds and co-authored > 50 publications and patents. Sarah is an active member of the UK life sciences community, with membership of SCI’s Board of Trustees alongside several other UK scientific advisory boards, and a long-standing commitment to teaching early career scientists. In 2021, Sarah was awarded the Creativity in Industry Prize (RSC).